Rhythm Pharmaceuticals, Inc. - Common Stock — Cash Flow (NASDAQ:RYTM) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -121.98 M-146 M-173.43 M-136.16 M-113.88 M-115.67 M -119.51 M Cash from investing activities 158.53 M-62.16 M28.03 M-5.67 M-48.17 M-137.15 M -104.91 M Cash from financing activities 2.01 M166.48 M213.83 M74.37 M191.24 M217.96 M 180.06 M Free cash flow -121.98 M-146 M-173.43 M-136.16 M-113.88 M-156.63 M -119.51 M

News

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Rhythm Pharmaceutical

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow (NASDAQ:RYTM) 2026-03-24

Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat